Jim Cramer Answered Questions About These 10 Stocks Recently

7. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Number of Hedge Fund Holders: 19

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the stocks Jim Cramer answered questions about recently. A caller asked Cramer for his opinion on the stock, and noted that it was rated a moderate buy by analysts and outperformed the S&P 500 by 60%. He replied:

“Okay, here’s the way we’re going to approach this: This is a pure spec, okay? I mean, total spec, $300 million company… I say you own it, but count it as part of your speculative part of your portfolio, and no more than that.”

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a biotechnology company developing gene therapies using its proprietary vector platform, with programs targeting retinal diseases, cystic fibrosis, geographic atrophy, alpha-1 antitrypsin deficiency, and Fabry disease. At the end of July, the company reported strong interim results from its Phase 2a SPECTRA trial of 4D-150 in diabetic macular edema, showing durable vision gains, improved retinal thickness, and a major reduction in supplemental injections compared to standard aflibercept treatment, with no cases of inflammation or serious safety concerns through 60 weeks.